Physician profile
Frederic Mark Ettner
NPI 1891859468
$3,072.78
in general payments reported to CMS, 2019-2025
27 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $235 · 2021: $619 · 2022: $405 · 2023: $571 · 2024: $603 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.77 | 2019-2025 | |
| Antares Pharma, INC. | $686.54 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $247.16 | 2020-2025 | |
| Halozyme INC | $139.08 | 2023 | |
| Exact Sciences Corporation | $138.74 | 2023-2025 | Cologuard Collection Kit |
| Cranial Technologies, INC | $126.76 | 2019-2024 | Doc Band |
| Clarus Therapeutics INC. | $109.33 | 2021 | |
| Ascend Therapeutics US, LLC | $83.49 | 2020-2023 | |
| Glaxosmithkline, LLC. | $79.58 | 2023-2024 | Shingrix, Arexvy |
| Novo Nordisk INC | $68.53 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $66.59 | 2025 | Repatha |
| Verity Pharmaceuticals INC. | $63.47 | 2025 | Tlando |
| Amarin Pharma, INC. | $59.45 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.82 | 2024 | Camzyos, Eliquis |
| Inspire Medical Systems, INC. | $36.31 | 2023-2024 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $36.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.74 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $32.20 | 2019 | |
| Qol Medical, LLC | $31.99 | 2023 | Sucraid |
| Allergan, INC. | $25.47 | 2019 | |
| Avion Pharmaceuticals | $23.47 | 2023 | Divigel |
| Vertical Pharmaceuticals, LLC | $23.29 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.44 | 2022 | |
| Lilly USA, LLC | $15.17 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.14 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.95 | 2025 | |
| Horizon Therapeutics Plc | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Ettner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.